Unknown

Dataset Information

0

Fratricide-resistant CD1a-specific CAR T cells for the treatment of cortical T-cell acute lymphoblastic leukemia.


ABSTRACT: Relapsed/refractory T-cell acute lymphoblastic leukemia (T-ALL) has a dismal outcome, and no effective targeted immunotherapies for T-ALL exist. The extension of chimeric antigen receptor (CAR) T cells (CARTs) to T-ALL remains challenging because the shared expression of target antigens between CARTs and T-ALL blasts leads to CART fratricide. CD1a is exclusively expressed in cortical T-ALL (coT-ALL), a major subset of T-ALL, and retained at relapse. This article reports that the expression of CD1a is mainly restricted to developing cortical thymocytes, and neither CD34+ progenitors nor T cells express CD1a during ontogeny, confining the risk of on-target/off-tumor toxicity. We thus developed and preclinically validated a CD1a-specific CAR with robust and specific cytotoxicity in vitro and antileukemic activity in vivo in xenograft models of coT-ALL, using both cell lines and coT-ALL patient-derived primary blasts. CD1a-CARTs are fratricide resistant, persist long term in vivo (retaining antileukemic activity in re-challenge experiments), and respond to viral antigens. Our data support the therapeutic and safe use of fratricide-resistant CD1a-CARTs for relapsed/refractory coT-ALL.

SUBMITTER: Sanchez-Martinez D 

PROVIDER: S-EPMC6554538 | biostudies-literature |

REPOSITORIES: biostudies-literature

Similar Datasets

| S-EPMC9395272 | biostudies-literature
| S-EPMC9221015 | biostudies-literature
| S-EPMC10786140 | biostudies-literature
| S-EPMC6102094 | biostudies-literature
| S-EPMC10635362 | biostudies-literature
| S-EPMC7497903 | biostudies-literature
| S-EPMC6637939 | biostudies-literature
| S-EPMC56962 | biostudies-literature
| S-EPMC8894580 | biostudies-literature
| S-EPMC5834143 | biostudies-other